Literature DB >> 25922692

Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?

Abdulaziz Al Farsi1, Peter M Ellis1.   

Abstract

Entities:  

Year:  2015        PMID： 25922692      PMCID： PMC4387439          DOI： 10.3978/j.issn.2072-1439.2015.01.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

Review 1.  Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.

Authors:  Peter M Ellis; Khalid Al-Saleh
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-08       Impact factor: 6.312

2.  Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.

Authors:  Xin Sun; Matthias Briel; Stephen D Walter; Gordon H Guyatt
Journal:  BMJ       Date:  2010-03-30

3.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

4.  Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

Authors:  David R Spigel; Howard A Burris; F Anthony Greco; Dianna L Shipley; Elke K Friedman; David M Waterhouse; Robert C Whorf; R Brian Mitchell; Davey B Daniel; Jeffrey Zangmeister; J David Bass; John D Hainsworth
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

5.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

6.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

Review 7.  A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Authors:  Peter M Ellis; Normand Blais; Dennis Soulieres; Diana N Ionescu; Meenakshi Kashyap; Geoff Liu; Barb Melosky; Tony Reiman; Phillippe Romeo; Frances A Shepherd; Ming-Sound Tsao; Natasha B Leighl
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

Review 8.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.

Authors:  Marco Presta; Patrizia Dell'Era; Stefania Mitola; Emanuela Moroni; Roberto Ronca; Marco Rusnati
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-02       Impact factor: 7.638

9.  Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Authors:  Jin Soo Lee; Vera Hirsh; Keunchil Park; Shukui Qin; Cesar R Blajman; Reury-Perng Perng; Yuh-Min Chen; Laura Emerson; Peter Langmuir; Christian Manegold
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

10.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:  Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316
View more
  2 in total

1.  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).

Authors:  Baohui Han; Kai Li; Yizhuo Zhao; Baolan Li; Ying Cheng; Jianying Zhou; You Lu; Yuankai Shi; Zhehai Wang; Liyan Jiang; Yi Luo; Yiping Zhang; Cheng Huang; Qiang Li; Guoming Wu
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

2.  Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.

Authors:  Jianmiao Liang; Weiguang Gu; Jun Jin; Hua Zhang; Zecheng Chen; Yicong Tang; Shunda Zhang; Shuang Yang; Yanming Deng; Weineng Feng
Journal:  Ther Adv Med Oncol       Date:  2020-10-31       Impact factor: 8.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.